Novo Nordisk announced discontinuation of multiple pipeline programs amid leadership transition and lower obesity drug sales growth forecasts. The company is confronting fierce competition from Eli Lilly’s GLP-1 compounds and a burgeoning market for compounded semaglutide, impacting sales of flagship drugs Ozempic and Wegovy. Concurrently, Novo is pursuing legal action to curb knockoff GLP-1 compounding in the U.S. Despite challenges, Novo’s diabetes and obesity care revenue continues to grow, albeit at a slower pace than prior years.